ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1851

Different Disease Activity Trajectories in Early Axial Spondyloarthritis Lead to Significantly Different Long-term Outcomes : A Cluster-based Analysis of the DESIR Cohort

Benattar Leslie1, Anna Molto2, Laure Gossec3 and Resche Rigon Matthieu4, 1Cochin Hospital, Paris, Paris, Ile-de-France, France, 2Rheumatology Department, Cochin Hospital, APHP, Paris, France, Paris, France, 3Sorbonne University, INSERM; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, 4INSERM (UFR 1153), Saint Louis Hospital, Paris, Paris, France

Meeting: ACR Convergence 2020

Keywords: Cohort Study, Disease Activity, longitudinal studies, Outcome measures, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose:  AxSpA is a heterogeneous disease, leading to different treatment and follow-up modalities depending on the presentation, along with other elements (socio-economic, gender, etc..). In a previous work, we identified some disease activity trajectories in early axSpa, but we did not evaluate the long-term impact for patients in terms of outcomes such as function, work impairment or structural progression.

Objectives: To identify and describe different trajectories of activity over 5 years in patients with early axSpA and to determine the impact of each on long-term outcomes.

Methods: Prospective, multi-centre study (DESIR cohort) of patients with early inflammatory back pain suggestive of axSpA.

Disease activity trajectories were identified using the k-means method, which provides longitudinal clusters. Baseline characteristics were described and the probability to be associated with one Trajectory assessed by a multinomial regression.

Long term outcomes such as TNFi prescription, function (BASFI), work impairment, quality of life (SF36 scale) and structural progression, associated with each trajectory were identified using mixed models.

Results: 633 patients were included. Six trajectories of disease activity were identified: Trajectory A (n=140 patients, 25.4% of all patients): ‘Moderate disease activity’;  B (n=94, 17.1%) : ‘Persistent high disease activity’;  C (n=94, 17.1%) :‘Clinically important improvement’ (improvement of 1.36 points on the ASDAS between baseline and year 5)  ; D (n=79, 14.3%) :‘Persistent inactive disease activity’; E (n=78, 14.2%) :‘Almost major improvement’ (improvement of 1.8 points)  ; F (n=66 (12%) : ‘Persistent very high activity’.

The ‘Persistent low disease activity’ Trajectory was set as the reference trajectory: a university level of education was found to be predictive of belonging to the ‘Inactive disease’ trajectory (OR=3.04, 95% confidence interval [1.46 to 6.78]). Male gender (OR=2.99 [1.56 to 5.92]), and a history of articular peripheral involvement (OR=4.34 [2.14 to 9.10]) were predictive of belonging to the ‘Almost major improvement’ trajectory, whereas a low degree of education (OR=0.27 [0.14 to 0.52]), and female gender (OR=2.01 [1.03 to 4.34])were associated with the ‘Persistent very high disease activity’ trajectory.

All trajectories were associated with a higher TNFi prescription. Higher activity trajectories were associated to other poorer outcomes : the ‘Persistent very high disease activity’ and ‘Persistent high disease activity’ Trajectories presented respectively a mean of 189 and 95 more days of sick leave over 5 years than the reference Trajectory, but also significantly lower SF-36 scores, poorer BASFI and BASMI. However, no higher likelihood of structural progression was observed in high disease activity groups.

Conclusion: We identified 6 trajectories of ASDAS-CRP. Gender, a university level of education, and peripheral joint involvement were the main factors differentiating trajectories at baseline. Higher disease activity trajectories were significantly associated with poorer function, more days of sick leave, and poorer quality of life. Interestingly, no Trajectories were found to be predictive of structural progression.

Figure : Trajectories of disease activity in early axial spondyloarthritis according to k-means technique. ASDAS, Ankylosing Spondylitis Disease Activity Score.

Table : Outcomes associated with distinct disease activity trajectories in early axial spondyloarthritis (mixed model)


Disclosure: B. Leslie, None; A. Molto, ABBVIE, 5, BMS, 5, 8, LILLY, 5, NOVARTIS, 5, 8, UCB, 5, 8, GILEAD, 5; L. Gossec, None; R. Matthieu, None.

To cite this abstract in AMA style:

Leslie B, Molto A, Gossec L, Matthieu R. Different Disease Activity Trajectories in Early Axial Spondyloarthritis Lead to Significantly Different Long-term Outcomes : A Cluster-based Analysis of the DESIR Cohort [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/different-disease-activity-trajectories-in-early-axial-spondyloarthritis-lead-to-significantly-different-long-term-outcomes-a-cluster-based-analysis-of-the-desir-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/different-disease-activity-trajectories-in-early-axial-spondyloarthritis-lead-to-significantly-different-long-term-outcomes-a-cluster-based-analysis-of-the-desir-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology